ALK基因抑制剂治疗非小细胞肺癌脑转移的研究进展  

Progress of ALK gene inhibitors in the treatment of brain metastases from non-small cell lung cancer

作　　者：孙文宇[1] 闫鹏飞[2] 原颖丽 马克威[1] Sun Wenyu Yan Pengfei Yuan Yingli Ma gewei(Department of Oncology, First Hospital of Jilin Universi- ty, Jilin 130021, China)

机构地区：[1]吉林大学第一医院肿瘤中心,130021 [2]佳木斯大学附属第一医院骨外科

出　　处：《国际肿瘤学杂志》2017年第6期472-475,共4页Journal of International Oncology

摘　　要：间变性淋巴瘤激酶（ALK）重排是非小细胞肺癌（NSCLC）强有力的致癌驱动基因之一，伴ALK重排的NSCLC患者应用第一代ALK抑制剂如克唑替尼的治疗疗效要远远优于化疗。同时越来越多的研究报道了ALK抑制剂在伴有脑转移的NSCLC患者中的颅内有效率。然而尽管第一代ALK抑制剂治疗ALK阳性NSCLC脑转移有初步的临床数据，但在获得性耐药后，肿瘤出现不同程度的复发，给肿瘤患者的后续治疗带来新的挑战。新一代ALK抑制剂如艾乐替尼、色瑞替尼、AP26113和PF-06463922的相继出现解决了这一问题。Anaplastic lymphoma kinase （ALK） rearrangement is one of the most potent carcinogenic genes in non-small cell lung cancer （NSCLC）. The first-generation ALK inhibitor such as crizotinib is superior to chemotherapy for NSCLC patients with ALK rearrangement. At the same time, more and more studies have reported ALK inhibitors in brain metastases of NSCLC patients with intracranial efficiency. However, despite the initial clinical data of first-generation ALK inhibitors in the treatment of ALK-positive NSCLC with brain metastases, different degrees of recurrence of tumors after acquired resistance have posed new challenges for fol- low-up treatment of cancer patients. A new generation of ALK inhibitors, such as alectinib, ceritinib, AP26113 and PF-06463922 have emerged to solve this problem.

关 键 词：癌 非小细胞肺 肿瘤转移 间变性淋巴瘤激酶融合基因抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]